3+ hour, 53+ min ago  (595+ words) Kavout | AI Celcuity's REVTORPYK Approval: A Multi-Billion Dollar Breakthrough Despite High Expectations - Celcuity Inc. secured early FDA approval for REVTORPYK (gedatolisib) on July 14, 2026, for HR+/HER2- breast cancer, ahead of its anticipated PDUFA date. - REVTORPYK is a first-in-class pan-PI3K/mTOR inhibitor,…...